目的:研究杀伤性人工抗原提呈细胞(KaAPC)治疗小鼠皮肤移植排斥的效果及其对治疗鼠整体免疫功能的影响。方法:利用可生物降解的聚乳酸-羟基乙酸共聚物微米球做载体,共价吸附H-2Kb抗原和anti-Fas等负性调节分子,制备针对同种反应性T细胞的特异性KaAPC,治疗以C57BL/6和BALB/c为供受对的小鼠皮肤移植排斥,并利用混合淋巴细胞培养观察治疗鼠对第三方供体的同种反应能力以及通过载瘤实验观察治疗鼠的抗肿瘤能力等,以论证KaAPC治疗对机体整体免疫功能的影响,帮助筛选有效治疗方案。结果:成功制备KaAPC,FACS验证其有正确的表型;KaAPC输注使皮肤移植物的存活时间明显延长,P<0.000 1,但并未显著损伤治疗鼠T细胞对第三方供体鼠脾细胞的同种增殖能力,也并未显著损伤治疗鼠的抗肿瘤能力。结论:KaAPC可以抑制小鼠皮肤移植排斥并对治疗鼠的整体免疫功能无明显损伤。 |
[1] LAU H T,YU M,FONTANA A,et al.Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice[J].Science,1996,273(5271):109-112.
[2] WHARENBY K A,STRALEY E E,KIM H,et al.Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation[J].Blood,2002,100(9):3147-3154.
[3] STRAUSS G,OSEN W,KNAPE I,et al.Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity[J].Cell Death Differ,2007,14(3):480-488.
[4] MIN W P,GORCZYNSKI R,HUANG XY,et al.Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival[J].J Immunol,2000,164(1):161-167.
[5] YOLCU ES,ASKENASY N,SINGH NP,et al.Cell membrane modification for rapid display of proteins as a novel means of immunomodulation:Fas L-decorated cells prevent islet graft rejection[J].Immunity,2002,17:795-808.
[6] KIM S H,KIM S,OLIGINO T J,et al.Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL[J].Mol Ther,2002,6(5):584-590.
[7] CHUANG Y H,SUEN J L,CHIANG B L,et al.Fasligand-expressing adenovirus-transfected dendritic cells decrease allergen-specific T cells and airway inflammation in a murine model of asthma[J].J Mol Med,2006,84(7):595-603.
[8] SCHUTZ C,FLECK M,MACHENSEN A,et al.Killer-artificial-antigen-presenting-cells (KaAPC):a novel strategy to delete specific T cells[J].Blood,2008,111(7):3546-3552.
[9] SCHUTZ C,OELKE M,SCHNECK J P,et al.Killer artificial antigen-presenting cells:the synthetic embodiment of a 'guided missile'[J].Immunotherapy,2010,2(4):539-550.
[10] 徐同生,刘祯,庆李鑫,等.游离皮瓣移植术结束前泵注右美托咪定对病人苏醒期的影响[J].现代医学,2015,43(1):92-94.
[11] 董伟民,陈宝安,丁家华,等.移植前选择性去除同种异体反应供者淋巴细胞预防移植物抗宿主病的实验研究[J].现代医学,2006,34(2):77-80.
[12] SINGH M,CHAKRAPANi A,O'HAGAN D.Nanoparticles and microparticles as vaccine-delivery systems[J].Expert Res Vaccines,2007,6(5):797-808.
[13] KOHANE D S.Microparticles and nanoparticles for drug delivery[J].Biotechnol Bioeng,2007,96(2):203-209.
[14] ZHAO H,SAATCHI K,HAFELI U O,et al.Preparation of biodegradable magnetic microspheres with poly(lactic acid)-coated magnetite[J].J Magnetism and Magnetic Materials,2009,321:1356-1363. |